Loading
A phase 2/3 trial testing IBI310 in hepatocellular carcinoma, now recruiting.
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment is a phase 2/3 interventional study registered as NCT07490262, led by Innovent Biopharmaceutical Technology (Hangzhou), and recruiting on the registry. Official title: A Randomised, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma. Planned enrolment is 680 participants (estimated). The study started in 2026-03-27 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/